World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 17 October 2016
Main ID:  ISRCTN57643242
Date of registration: 20/08/2014
Prospective Registration: Yes
Primary sponsor: Faculty of Life Sciences and Computing, London Metropolitan University (UK)
Public title: Omega 3 fatty acid treatment in patients with epilepsy
Scientific title: Omega 3 fatty acid supplementation to prevent seizure in patients with refractory epilepsy
Date of first enrolment: 01/09/2014
Target sample size: 70
Recruitment status: Completed
URL:  http://isrctn.com/ISRCTN57643242
Study type:  Interventional
Study design:  Double-blind placebo-controlled randomised intervention trial (Treatment)  
Phase: 
Countries of recruitment
Sudan
Contacts
Name:    
Address: 
Telephone:
Email:
Affiliation: 
Name: Kebreab    Ghebremeskel
Address:  Lipidomics and Nutrition Research Centre Faculty of Life Sciences and Computing London Metropolitan University 166-220 Holloway Road N7 8DB London United Kingdom
Telephone: -
Email: k.ghebremeskel@londonmet.ac.uk
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: Patients with refractory idiopathic epilepsy, aged 17 to 50 years
Exclusion criteria: 1. Age under 17 and over 50 years
2. Other diseases in addition to epilepsy
3. Structural lesions
4. Pregnancy
5. Responsive to AED
6. Less than two seizures a month


Age minimum:
Age maximum:
Gender: Both
Health Condition(s) or Problem(s) studied
Epilepsy
Nervous System Diseases
Epilepsy
Intervention(s)
1. Active supplement (contains 1.5g DHA and 390mg EPA)
2. Placebo (1.9g of saturated and monounsaturated fatty acid blend)
Primary Outcome(s)
Complete elimination or reduction in the frequency seizures
Secondary Outcome(s)
1. Improvements of cognition, memory, and manifestations of behavioural and psychiatric disorders 2. Modulation of clinical markers of cardiac arrhythmias; down regulation of inflammatory markers
Secondary ID(s)
EPILOEMGA3 v1
Source(s) of Monetary Support
Lipidomics and Nutrition Research Centre, London Metropolitan University, London (UK), University of Khartoum Hospital (Sudan), Efamol Limited (UK)
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history